^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Anti-CD19/CD20/CD22 CAR T-Cells
i
Other names: Anti-CD19/CD20/CD22 CAR T-Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
2ms
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Sumithira Vasu | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
almost2years
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Sumithira Vasu | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 positive
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
almost2years
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1, N=36, Not yet recruiting, Sumithira Vasu
New P1 trial • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 positive
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
Share via
